Detailed explanation of venetoclax/venetoclax (venetoclax) onset time and treatment course evaluation recommendations

Venetoclax is an oral selective inhibitor of BCL-2, mainly used to treat patients with chronic lymphocytic leukemia (CLL) and some acute myeloid leukemia (AML). Its mechanism of action is by inhibiting the anti-apoptotic protein BCL-2, causing tumor cells to lose survival signals, thereby inducing apoptosis. Regarding the onset of effect, clinical data show that when Venetoclax is combined with other drugs, improvement in hematological indicators and decrease in white blood cell count can usually be observed within 2 to 4 weeks. Some patients may experience significant effects in the first month of treatment, but complete remission or molecular remission usually requires a longer course of treatment.

In terms of treatment course evaluation, doctors usually combine blood routine, bone marrow examination and imaging data to conduct a staged evaluation of the patient's efficacy. Initial efficacy evaluation focuses on reduction in white blood cell count, lymph node shrinkage, and hematological improvement. As the course of treatment progresses, bone marrow biopsy, MRD (minimum residual disease) detection and tumor burden assessment will be further used to determine whether a complete response or partial response has been achieved, thereby guiding subsequent treatment decisions.

VenetoclaxThe treatment design has certain individualized characteristics. A gradient escalation dose strategy is usually adopted at the initial stage of treatment to reduce the risk of tumor lysis syndrome (TLS), and treatment is maintained after reaching the target dose. The length of treatment depends on the type of disease, patient tolerance and efficacy. For example, patients with CLL usually need to be maintained for at least 12 months or more, while patients with AML may continue for several months during the induction and consolidation treatment phases. Renal function, electrolytes and routine blood tests need to be monitored regularly during the course of treatment in order to adjust the dosage or deal with adverse reactions in a timely manner.

While using Venetoclax, patients should cooperate with clinical follow-up and laboratory monitoring, and pay attention to lifestyle intervention, such as maintaining adequate hydration, avoiding high-risk infections, and adjusting medication as directed by the doctor. For patients with unsatisfactory efficacy or drug resistance, combination with other targeted drugs or chemotherapy regimens may be considered to prolong remission time and survival benefit. Overall, Venetoclax has the characteristics of rapid onset of effect and the treatment course can be individually adjusted, but scientific monitoring and treatment course evaluation are key links to ensure efficacy and safety.

Reference materials:https://www.drugs.com/